DP8 Stock Overview

A biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. More details

DP8 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue grew by 116.3% over the past year

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 33.1% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

CervoMed Inc. Competitors

2invest

XTRA:2INV

€67.3m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€15.2m

Heidelberg Pharma

XTRA:HPHA

€101.6m

Price History & Performance

Summary of share price highs, lows and changes for CervoMed
Historical stock prices
Current Share Price	US$2.14
52 Week High	US$2.18
52 Week Low	US$1.77
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	18.89%

Recent updates

Shareholder Returns

	DP8	DE Biotechs	DE Market
7D	18.9%	-0.8%	-1.6%
1Y	n/a	-13.0%	6.8%

Return vs Industry: Insufficient data to determine how DP8 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how DP8 performed against the German Market.

Price Volatility

Is DP8's price volatile compared to industry and market?
DP8 volatility
DP8 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: DP8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine DP8's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	8	John Alam	www.cervomed.com

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials.

CervoMed Inc. Fundamentals Summary

How do CervoMed's earnings and revenue compare to its market cap?
DP8 fundamental statistics
Market cap	€17.63m
Earnings (TTM)	-€11.49m
Revenue (TTM)	€9.68m

1.8x

P/S Ratio

-1.5x

P/E Ratio

Is DP8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DP8 income statement (TTM)
Revenue	US$10.07m
Cost of Revenue	US$14.57m
Gross Profit	-US$4.50m
Other Expenses	US$7.45m
Earnings	-US$11.95m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.45
Gross Margin	-44.71%
Net Profit Margin	-118.68%
Debt/Equity Ratio	0%

How did DP8 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 14:31
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CervoMed Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tyler Bussian	Brookline Capital Markets
Sumant Satchidanand Kulkarni	Canaccord Genuity
Daniil Gataulin	Chardan Capital Markets, LLC

CervoMed BST:DP8 Stock Report